Novo Nordisk A/S

🇩🇰Denmark

Country: 🇩🇰Denmark

Ownership: Public

Established: 1923-01-01

Employees: 63.3K

Market Cap: $602.2B

Website: http://www.novonordisk.com

Clinical Trials

Effect of Liraglutide on Absorption of Paracetamol in Subjects With Type 2 Diabetes

Phase 1

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: liraglutide
Drug: placebo
Drug: paracetamol

First Posted Date: 2012-01-25

Last Posted Date: 2017-01-26

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 18

Registration Number: NCT01517555

Locations: 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany

Effect of Liraglutide on Heart Frequency in Healthy Volunteers

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 2
Diabetes

Interventions: Drug: liraglutide
Drug: moxifloxacin
Drug: placebo
Procedure: electrocardiogram (ECG)

First Posted Date: 2012-01-24

Last Posted Date: 2017-01-25

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 64

Registration Number: NCT01516255

Locations: 🇺🇸
Novo Nordisk Investigational Site, Fargo, North Dakota, United States

Safety and Tolerability of Liraglutide in Healthy Japanese Male Volunteers

Phase 1

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: liraglutide
Drug: placebo

First Posted Date: 2012-01-24

Last Posted Date: 2017-01-25

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 24

Registration Number: NCT01515592

Locations: 🇯🇵
Novo Nordisk Investigational Site, Tokyo, Japan

Comparison of Two Liraglutide Formulations in Healthy Subjects

Phase 1

Completed

Conditions: Healthy
Diabetes

Interventions: Drug: liraglutide

First Posted Date: 2012-01-24

Last Posted Date: 2015-01-30

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 22

Registration Number: NCT01515579

Evaluation of Safety and Parameters of Application Technique

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 1
Diabetes Mellitus, Type 2
Delivery Systems

Interventions: Other: No treatment given

First Posted Date: 2012-01-24

Last Posted Date: 2016-11-06

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 4819

Registration Number: NCT01516242

Locations: 🇸🇰
Novo Nordisk Investigational Site, Bratislava, Slovakia

Bioequivalence of Two Liraglutide Formulations in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy
Diabetes

Interventions: Drug: liraglutide

First Posted Date: 2012-01-24

Last Posted Date: 2015-01-13

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 22

Registration Number: NCT01515553

Special Survey for Long Term Application

Completed

Conditions: Achondroplasia
Genetic Disorder

Interventions: Drug: somatropin

First Posted Date: 2012-01-24

Last Posted Date: 2017-02-27

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 395

Registration Number: NCT01516229

Locations: 🇯🇵
Novo Nordisk Investigational Site, Tokyo, Japan

First Human Dose Trial of NNC0195-0092 (Somapacitan) in Healthy Subjects

Phase 1

Completed

Conditions: Growth Hormone Disorder
Adult Growth Hormone Deficiency
Growth Hormone Deficiency in Children
Healthy

Interventions: Drug: somapacitan
Drug: placebo (somapacitan)

First Posted Date: 2012-01-23

Last Posted Date: 2020-12-24

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 105

Registration Number: NCT01514500

Locations: 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany

Comparison of Three Liraglutide Formulations in Healthy Volunteers

Phase 1

Completed

Conditions: Diabetes
Healthy

Interventions: Drug: liraglutide

First Posted Date: 2012-01-23

Last Posted Date: 2017-03-01

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 24

Registration Number: NCT01514487

Locations: 🇦🇺
Novo Nordisk Investigational Site, Adelaide, Australia

A Trial Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart and BIAsp 30 in Insulin naïve Subjects With Type 2 Diabetes

Phase 3

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: insulin degludec/insulin aspart

First Posted Date: 2012-01-20

Last Posted Date: 2019-03-26

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 394

Registration Number: NCT01513590

Locations: 🇺🇦
Novo Nordisk Investigational Site, Zhytomyr, Ukraine

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy